CADL – candel therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Candel Therapeutics (CADL) had its price target lowered by Citigroup Inc. from $24.00 to $22.00. They now have a "buy" rating on the stock.
Candel Therapeutics (CADL) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $25.00 price target on the stock.
Candel Therapeutics strengthens balance sheet as lead cancer therapy advances [Yahoo! Finance]
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
Candel Therapeutics (CADL) was upgraded by Zacks Research from "strong sell" to "hold".
Form S-8 Candel Therapeutics,
Form 10-K Candel Therapeutics, For: Dec 31
Form 8-K Candel Therapeutics, For: Mar 12
Form 4 Candel Therapeutics, For: Feb 23 Filed by: Manning Paul B
Form 8-K Candel Therapeutics, For: Feb 19
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.